Biocon starts clinical study to evaluate efficacy of Itolizumab
This is a phase-II randomised, double-blind, parallel-group, placebo and active-controlled (adalimumab), two-treatment period…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
itolizumab
Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis
Equalise is a phase-Ib open-label, proof-of-concept clinical study currently studying Lupus Nephritis patients in the Part B…
Biocon Q1FY22 revenue at Rs 1,808 crores, up six per cent
Biosimilars up 10 per cent at Rs 758 crores and research services up 41 per cent at Rs 595 crores
SEC asks Biocon to submit safety, mortality data for Itolizumab
The company claims that approximately 2000 COVID-19 patients used the drug under the emergency use authorisation
Health ministry decides against including Itolizumab in clinical management protocols for COVID-19
The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute…
Biocon presents key Insights into clinical study that enabled DCGI approval of Itolizumab
A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals…
Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial
Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe…
DCGI approves Itolizumab for restricted emergency use in COVID-19 treatment
The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by an expert committee,…
Biocon and Equillium expand exclusive licensing agreement for Itolizumab to include Australia and…
Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the US and…